ASND Reports €247M Q1 Rev, €197M YORVIPATH Rev, €44M SKYTROFA Rev, +146% YoY Rev, +94% YoY Net Income, +1,000+ New Patients, $187.5M RPU Sale
Ascendis Pharma A/S Ordinary Share · Now $218.82
-3.5% in 7d after detection
Post-detection moves
1h
—
1d
-3.0%
3d
-3.4%
7d
-3.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS